MDCX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Apr 29, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing

Nov 4, 2026

8-K

Nasdaq Confirms Compliance Restored After Company’s Shares Reclaim $1 Minimum Bid Price Requirement

Oct 23, 2026

8-K

Medicus Pharma Ltd. Announces 1-for-50 Share Consolidation

Oct 16, 2026

8-K

Medicus Pharma Announces 50-to-1 Share Consolidation to Regain Nasdaq Compliance

Oct 7, 2026

8-K

Medicus Pharma Terminates Standby Equity Purchase Agreement with Yorkville

Sep 14, 2026

8-K

Medicus Pharma Ltd. Awards Restricted Common Shares in Lieu of Cash Bonuses

Sep 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

425

NEWForm 425 - Prospectuses and communications, business combinations

Nov 9, 2026

425

Form 425 - Prospectuses and communications, business combinations

Nov 6, 2026

424B3

UPDATE TO PRIOR PROSPECTUS | Shares: 3,245,595

Nov 6, 2026

425

Form 425 - Prospectuses and communications, business combinations

Nov 4, 2026

424B3

UPDATE TO PRIOR PROSPECTUS | Shares: 64,911

Oct 23, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Oct 16, 2026

Registrations

TYPE

HEADLINE

FILED AT

POS AM

Form POS AM - Post-Effective amendments for registration statement

Mar 25, 2026

POS AM

Form POS AM - Post-Effective amendments for registration statement

Mar 25, 2026

POS AM

Form POS AM - Post-Effective amendments for registration statement

Mar 25, 2026

S-3

SHARE RESALE REGISTRATION

Jan 30, 2026

DRS

Form DRS - Draft Registration Statement

Jan 12, 2026

S-3

December 2025 SHELF | Offering amount: $100,000,000 | Float: 18,643,229 | Amount sold to date: $0

Dec 29, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 30, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 19, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 1, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 21, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jun 30, 2025

PRER14A

Form PRER14A - Preliminary Proxy Soliciting materials

Jun 23, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

Melani Kenneth R. (Filed by)

Oct 16, 2026

SCHEDULE 13D

Bokhari Raza (Filed by)

Sep 14, 2026

Smith Andrew Alasdair (Reporting)

Sep 8, 2026

Mehmud Faisal (Reporting)

Sep 8, 2026

Brennan Edward J. (Reporting)

Sep 8, 2026

Bonner Carolyn F. (Reporting)

Sep 8, 2026

Other

TYPE

HEADLINE

FILED AT

Medicus Pharma Ltd. Common Stock MDCX · SEC Filings